#1 Clinical Trials Search in Europe

Difelikefalin

Difelikefalin is an investigational drug being studied in clinical trials for its potential to treat moderate to severe itching (pruritus) associated with various conditions. This article summarizes key information from recent clinical trials exploring the use of difelikefalin for chronic itch in patients with kidney disease, atopic dermatitis, and other pruritus-related disorders.

Table of Contents

What is Difelikefalin?

Difelikefalin, also known as CR845, is a new medication being studied for its potential to treat various forms of chronic itching (pruritus)[1]. It is designed to provide relief for patients suffering from persistent and severe itching associated with certain medical conditions.

What Conditions Does Difelikefalin Treat?

Difelikefalin is being investigated for several conditions characterized by chronic itching:

  • Chronic Kidney Disease (CKD)-associated Pruritus: This is itching that occurs in patients with advanced kidney disease, especially those on dialysis[1].
  • Atopic Dermatitis: Also known as eczema, this is a condition that causes dry, itchy skin[3].
  • Notalgia Paresthetica: A nerve disorder causing itching and discomfort in the upper back[6].
  • Uremic Pruritus: Another term for the itching associated with kidney disease[7].

How Does Difelikefalin Work?

Difelikefalin works by targeting specific receptors in the body called kappa opioid receptors. These receptors are involved in the sensation of itching. By activating these receptors, difelikefalin helps to reduce the intensity of itching sensations, providing relief to patients[1].

How is Difelikefalin Administered?

Difelikefalin is being studied in different forms of administration:

  • Intravenous (IV) Injection: For patients on hemodialysis, difelikefalin is given as an injection into the dialysis line at a dose of 0.5 micrograms per kilogram of body weight after each dialysis session, typically three times per week[1].
  • Oral Tablets: For other conditions, difelikefalin is being tested as oral tablets taken once or twice daily. Doses being studied range from 0.25 mg to 2.0 mg[3][8].

Current Clinical Trials

Difelikefalin is currently being studied in several clinical trials:

  • Chronic Kidney Disease: Studies are evaluating its effectiveness in reducing itching in adults on hemodialysis[1] and in adolescents aged 12-17 years[2].
  • Atopic Dermatitis: Trials are assessing difelikefalin’s ability to reduce itching in adults with moderate to severe eczema[3].
  • Notalgia Paresthetica: Research is ongoing to determine if difelikefalin can help with the itching associated with this nerve disorder[6].
  • Advanced Chronic Kidney Disease: Studies are looking at oral difelikefalin for patients with advanced kidney disease who are not on dialysis[8].

Potential Side Effects

As with any medication, difelikefalin may cause side effects. The ongoing clinical trials are carefully monitoring patients for any adverse events (unwanted effects). The most common side effects and their frequency are not yet fully known, as the drug is still in the testing phase. Patients participating in clinical trials are closely monitored for any potential side effects[2].

It’s important to note that difelikefalin is still an investigational drug, which means it has not yet been approved for general use by regulatory agencies like the FDA. The ongoing clinical trials will help determine its safety and effectiveness before it can be made widely available to patients[1][3].

Aspect Details
Drug Name Difelikefalin (also known as CR845)
Primary Indications Moderate to severe pruritus associated with chronic kidney disease, atopic dermatitis, notalgia paresthetica
Administration Routes Intravenous injection, oral tablets
Key Trial Phases Phase 1, Phase 2, Phase 3
Common Trial Durations 8-12 weeks (primary treatment period), up to 52 weeks (extension phases)
Primary Outcome Measures Changes in itch intensity, proportion of patients achieving significant itch reduction
Secondary Outcomes Quality of life improvements, sleep quality, skin condition assessments
Safety Assessments Adverse events, pharmacokinetics, tolerability
Special Populations Adults, adolescents (some trials)

FAQ

  • What is difelikefalin and how does it work? Difelikefalin is an investigational drug that targets kappa opioid receptors to reduce itching sensations. It is being studied as a potential treatment for moderate to severe pruritus (itching) associated with various conditions.
  • What conditions is difelikefalin being studied for? Clinical trials are evaluating difelikefalin for pruritus related to chronic kidney disease, atopic dermatitis, notalgia paresthetica, and other itch-causing disorders.
  • How is difelikefalin administered in clinical trials? Difelikefalin is being studied in both oral tablet form (taken by mouth) and as an intravenous injection. The specific dosing and administration depend on the particular trial and condition being studied.
  • What are some of the main outcomes being measured in difelikefalin trials? Key outcomes include changes in itch intensity (often measured by numeric rating scales), proportion of patients achieving significant itch reduction, quality of life improvements, and safety assessments.
  • How long do the clinical trials for difelikefalin typically last? The duration varies, but many trials include treatment periods of 8-12 weeks, with some having longer extension phases up to 52 weeks to assess long-term safety and efficacy.

Ongoing Clinical Trials on Difelikefalin

  • Study on the Safety of Difelikefalin for Adolescents with Itching Due to Chronic Kidney Disease on Hemodialysis

    Recruiting

    1 1 1
    Investigated drugs:
    Greece Italy Portugal Spain

  • Study on the Effectiveness and Safety of Difelikefalin for Adults with Moderate-to-Severe Itching from Notalgia Paresthetica

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Germany Poland Spain

Glossary

  • Pruritus: The medical term for itching, which can be a chronic and distressing symptom in various conditions.
  • Hemodialysis: A medical procedure that filters waste products from the blood when the kidneys are not working properly.
  • Atopic Dermatitis: A chronic skin condition characterized by itchy, inflamed skin, also known as eczema.
  • Notalgia Paresthetica: A nerve disorder causing chronic itching and altered sensation in the upper back area.
  • Numeric Rating Scale (NRS): A tool used to measure the intensity of symptoms like itching, typically on a scale from 0 to 10.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Open-label Extension: A phase of a clinical trial where all participants receive the active treatment, often following a placebo-controlled period.
  • Topical Corticosteroid (TCS): A type of anti-inflammatory medication applied directly to the skin to treat conditions like atopic dermatitis.
  • Efficacy: The ability of a treatment to produce a desired effect or outcome in ideal conditions.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.

References

  1. https://clinicaltrials.gov/study/NCT05031546
  2. https://clinicaltrials.eu/trial/study-on-the-safety-of-difelikefalin-for-adolescents-with-itching-due-to-chronic-kidney-disease-on-hemodialysis/
  3. https://clinicaltrials.gov/study/NCT04018027
  4. https://clinicaltrials.gov/study/NCT05885763
  5. https://clinicaltrials.gov/study/NCT05978063
  6. https://clinicaltrials.gov/study/NCT04706975
  7. https://clinicaltrials.gov/study/NCT05885737
  8. https://clinicaltrials.gov/study/NCT05342623